Bruker (BRKR) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Bruker (BRKR) overview

Bruker (BRKR) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 3,437m and operating profit of USD 68.2m; the year-end share price was 47.11 USD and market capitalisation was USD 7,167m. Bruker is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bruker's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 2,457mFY 2025
Share price47.11 USDFY 2025 year end
RevenueUSD 3,437mFY 2025
Operating profitUSD 68.2mFY 2025
Net earningsUSD -8.6mFY 2025
Market capitalisationUSD 7,167mFY 2025 year end

About Bruker

Bruker develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions for examining chemical, biological, and industrial samples. Its technologies include magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology, and molecular spectroscopy. Products and services support research, diagnostics, and applied markets. Customers include academic and government research facilities, pharmaceutical and biotechnology companies, and laboratories in clinical, food, chemical, and industrial fields.

Generate the Bruker report

Bruker is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Bruker and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Bruker

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.